Introduction
============

Hepatocellular carcinoma (HCC) is the most common neoplasm of primary liver cancers, accounting for 85-90% of all cases. The incidence of HCC trends up annually makes it to be the second leading cause of cancer death in East Asia and the sixth in western countries [@B1], [@B2]. The failure of early diagnosis, deficiency of effective therapeutic targets and surveillance contribute to the poor prognosis of HCC. Thus, identifying new targets for therapeutic intervention and developing novel diagnostic approaches are in great need for early diagnosis and intervention for HCC.

Like other cancers, the pathogenesis of HCC is a long process involving complicated genetic and epigenetic alterations. Accumulating evidences has demonstrated the importance of long noncoding RNAs (LncRNAs) in the pathogenesis of cancers with diverse functions and mechanisms. LncRNAs are a class of transcripts, which are longer than 200 nucleotides in length with or without poor protein coding capacity [@B3], [@B4]. Many lncRNAs have been well elucidated in carcinogenesis. For examples, HOTAIR modulates cancer epigenome in breast cancer [@B5], MALAT1 regulates genes expression related to metastasis in lung cancer [@B6], and XIST plays tumor-suppressive role in hematologic cancer [@B7]. Intriguingly, the expression of lncRNAs is strikingly tissue-specific compared with protein coding genes [@B8], [@B9]. Additionally, lncRNAs may play roles in tumorigenesis through reprogramming the glucose metabolism [@B10], [@B11].

In our previous study, RNA-Seq has been applied to identify important genes and noncoding RNAs involved in the HCC carcinogenesis and development. Three pairs of HCC tumor and nontumor tissues were sequenced and compared [@B12]. Downregulation of a cytoplasmic long intergenic noncoding RNA, *LINC01554*, was detected in the three tested HCC tissues. Moreover, according to GEPIA (Gene Expression Profiling Interactive Analysis) [@B13], *LINC01554* is highly expressed in liver in comparison to other organs in human body (Figure [S1](#SM0){ref-type="supplementary-material"}).

The aberration of glucose metabolism is one of the hall markers of human cancers. Enhanced glycolytic effect has proved to promote cancer cell proliferation as well as metastasis [@B14]. Pyruvate kinase is a key rate-limiting enzyme to catalyze the conversion of phosphoenolpyruvate (PEP) and ADP to pyruvate acid and generates ATP in the last step of aerobic glycolysis. There are different mammalian isoforms of pyruvate kinase, including pyruvate kinase isozymes M1 (PKM1), pyruvate kinase isozymes M2 (PKM2), and pyruvate kinase liver and red blood cells (PKLR). Among them, the aberrant expression PKM2 is most common pathogenic subtype in cancers [@B15], [@B16]. Notably, a small group of lncRNAs such as LINC-LET [@B17] and LINC-p21 [@B18], have been reported to regulate the activity of PKM2.

Here, our data indicate that downregulation of *LINC01554* is correlated with poor outcome in patients with HCC. *LINC01554* downregulation restrains aerobic glycolysis and tumor growth. Mechanistically, *LINC01554* promotes proteasomal degradation of PKM2 and inhibits Akt/mTOR signaling pathway to decrease the aerobic glycolytic level in HCC cells. Its tumor-suppressive function and underlying mechanisms were characterized.

Materials and Methods
=====================

Clinical specimens
------------------

A total of 167 primary HCC samples, including tumor and adjacent non-tumor liver tissues, were collected from HCC hepatectomy in Sun Yat-Sen University Cancer Center (Guangzhou, China). Tissue specimens used in this study were reviewed and approved by the Committees for Ethical Review of Research at Sun Yat-sen University Cancer Center.

5\' and 3\' rapid amplification of cDNA ends (RACE), coding potential and secondary structure prediction of LINC01554
---------------------------------------------------------------------------------------------------------------------

The transcriptional initiation and termination of *LINC01554* were determined by 5\' RACE and 3\' RACE, respectively, with a SMART™ RACE cDNA Amplification Kit (Clontech, USA) following the manufacturer\'s instructions. The sequences for the gene-specific PCR primers used for 5\' and 3\' RACE analysis were listed in Table [S1](#SM0){ref-type="supplementary-material"}. The amplified products were gel purified, cloned into pGEM-T vector and confirmed by sequencing. The full-length sequence of *LINC01554* determined by 5\' and 3\' RACE is presented in Figure [S2](#SM0){ref-type="supplementary-material"}A-C, and the transcript size of *LINC01554* was validated to be 1943 bp. The coding potential of *LINC01554* was estimated using the LINCipedia [@B18]. The PhyloCSF score was 13.8064 (with a score \> 60.7876 indicating a potential coding gene) and the CPAT coding probability was 21.94% (with a score \> 36.4% indicating a potential coding gene), supporting the protein-noncoding feature of *LINC01554* (Figure [S2](#SM0){ref-type="supplementary-material"}D). Highly stable secondary structure of *LINC01554* was predicted using RNAfold Webserver (Figure [S2](#SM0){ref-type="supplementary-material"}E).

Northern blot analysis
----------------------

10 μg of total RNA samples isolated from MIHA and 7701 were separately subjected to electrophorese to 1% (wt/vol) agarose formaldehyde gels using NorthernMax^TM^ Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturers\' protocols, and then transferred to a positive charged nylon membrane (GE Healthcare, Little Chalfont, Buckinghamshire, UK). The digoxigenin labeled *LINC01554* DNA probe was purchased from Exonbio Lab (Guangzhou, China). After pre-hybridization for 30 min, the membrane was hybridized for 12 h at 42 °C in ULTRAhyb buffer containing the denatured probe. After washing, signal on the membrane was detected by DIG Wash and Block Buffer Set (Sigma, St. Louis, MO) according to the manufacturer\'s instructions.

Cell lines and plasmids
-----------------------

The human immortalized liver cell line MIHA and HCC cell lines BEL7402, QGY7701, QGY7703, SMMC7721, PLC8024, HepG2, Huh7 and Hep3B were employed in this study and their background information has been reported previously [@B20]. Full-length *LINC01554* was cloned into pcDNA3.1(+) vector (Invitrogen, Carlsbad, CA ), and stably transfected into HCC cell lines BEL7402 and QGY7701 by hilymax (DOJINDO, Japan) according to the manufacturer\'s instructions.

Knockout LINC01554 by CRISPR/Cas9
---------------------------------

*LINC01554* KO cells were generated using the CRISPR/Cas9 genome editing system. Briefly, two sgRNAs that targeted *LINC01554* were separately transfected into 293FT cells as well as lenti-Cas9-EGFP vector. sgRNAs sequences were listed in Table [S1](#SM0){ref-type="supplementary-material"}. All plasmids were purchased from Genecopoeia (Rockville, MD), including CP-LvC9NU-02 for construction of Cas9-EGFP and pCRISPR-LvSG03 for sgRNAs. Cas9-expressing cells (SMMC7721-Cas9) was established followed by co-infection of two sgRNAs. PCR and T7 endonuclease I cleavage were performed to detect the genomic deletions of isolated single colonies. The genomic deletions were validated by sequencing after cloning the corresponding PCR products into T vector (Takara, Japan).

RNA isolation and qRT-PCR
-------------------------

Total RNA of HCC samples and cell lines was isolated by TRIZOL Reagent (Invitrogen) following reverse transcription using the Evoscript Universal cDNA Master (Roche). qRT-PCR was performed to determine the relative RNA level using the SYBR Green method on Roche LightCycler® 480 PCR system. β-actin was employed as an endogenous control. Taqman MicroRNA reverse transcription kit (Applied Biosystems, Foster City, CA) was used to reversely transcript miR-365a and U6. TaqMan MicroRNA Assays (Applied Biosystems) were then applied to quantitating it. U6 small nuclear RNA was served as an internal control. The relative expression level of RNAs was calculated through the comparative C~t~ formula. All the primer sequences used in this study were listed in the Table [S1](#SM0){ref-type="supplementary-material"}.

Subcellular fractionation analysis
----------------------------------

Subcellular isolation of RNAs in MIHA and SMMC7721 cells was conducted by Cytoplasmic and Nuclear RNA Purification Kit (Norgenbiotek Corporation, Thorold, ON, Canada) according to the manufacturer\'s instructions. Cytoplasmic and nuclear fractions were determined by qRT-PCR.

Functional assays *in vitro*
----------------------------

Cell proliferation assay, non-adherent colony formation assay, and foci formation assay were used to evaluate the biological function of *LINC01554 in vitro*. Cell proliferation assay was performed by using the Cell Counting Kit-8 (CCK8; Dojindo, Kumamoto, Japan) according to the manufacturer\'s instructions. As foci formation assay, 1 × 10^3^ cells were seeded in 6-well plates, and cell colonies (\> 50 cells/colony) were counted by 1% crystal violet staining after one week. For non-adherent colony formation assay, 5 × 10^3^ cells were suspended in soft agar mixture, which was made up of Dulbecco\'s modified Eagle medium, 10% fetal bovine serum, and 0.35% SeaPlaque agarose. The suspension mixture subsequently was overlaid on the solidified 0.5% agar base. After two weeks, colonies were counted under the microscope in 10 fields per well and photographed. All the results were expressed as the mean ± SD of triplicate independent experiments.

Functional assay *in vivo*
--------------------------

Subcutaneous xenograft tumor model was used to estimate the effects of *LINC01554* on tumorigenicity *in vivo*. Tested cells (3 × 10^6^ cells for 7402-*LINC01554*, 4 × 10^6^ cells for 7701-*LINC01554*, 4 × 10^6^ cells for 7721-KO) and control cells (7402-Vec, 7701-Vec, 7721-WT) were subcutaneously injected into the right and left dorsal flank of 4-week-old male BALB/C nude mice (Guangdong Animal Center, Guangzhou, China), respectively. Tumor size was measured and calculated as: V (mm^3^) = 0.5×L×W^2^ (L, long axis of tumor; W, short axis of tumor). About three to four weeks later, the tumors were isolated, weighted and fixed in the formaldehyde solution. All animal experiments were conducted in accordance with the Institutional Animal Care and Use Committee guidelines at Sun Yat-sen University Cancer Center.

Metabolic assays
----------------

Cells were seeded in 6-well plate and cultured for 24 h, then culture medium was collected and glucose, lactate and pyruvate were examined by glucose assay kit, lactate assay kit and pyruvate assay kit, respectively. For intracellular ATP measurement, cells were collected and ATP assay kit was applied according to manufacturer\'s protocol. The kits were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Results were normalized by protein concentration and triple independent experiments were performed.

LncRNA fluorescence *in situ* hybridization (FISH) and immunofluorescence staining
----------------------------------------------------------------------------------

RNA FISH was performed on cells, HCC tumor and pairing nontumor tissues using RNA Fluorescence In Situ Hybridization Kit (Exonbio Lab, Guangzhou, China) as previously described [@B21]. Probes sequences were listed in Table [S1](#SM0){ref-type="supplementary-material"}, designed by Exonbio Lab (Guangzhou, China). RNA FISH and immunofluorescence staining were combined to detect the colocalization of *LINC01554* and PKM2 in cells. Hybridization with lncRNA probes was first performed at 37 °C for 4 h, then incubated with rabbit anti-PKM2 antibody (1: 100 dilution, \#4053, Cell Signaling Technology, Danvers, MA) overnight at 4 °C. After secondary antibodies incubation, Tyramide signal amplification (Exonbio Lab, Guangzhou, China) and DAPI (Abcam, Cambridge, MA) staining, the images were captured by confocal microscope (Olympus FV1000, Tokyo, Japan).

Antibodies and western blot assay
---------------------------------

Western blot assay were performed according to the standard protocol. Information of antibodies is listed in the Table [S2](#SM0){ref-type="supplementary-material"}.

RNA pull-down assay and mass spectrometry
-----------------------------------------

RNA pull-down assay was performed using Pierce Magnetic RNA-Protein Pull-down kit (Thermo scientific, Rockford, IL) according to the manufacturer\'s instructions. Briefly, sense and antisense RNAs were *in vitro* transcripted by T7 RNA polymerase using MEGAscript kit (Ambion, Carlsbad, CA) and labeled by Pierce RNA 3\' Desthiobiotinylation Kit (Thermo Scientific, Rockford, IL), finally purified by phenol:chloroform mixture. 50 pmol biotin-labeled RNA was mixed with 50 μL streptavidin magnetic beads for 30 min at room temperature with rotation, then incubated with cell lysates. The eluted proteins were detected by western blot analysis and later mass spectrometry on a MALDI-TOF-MS instrument (Bruker Daltonics).

RNA immunoprecipitation assay
-----------------------------

RNA immunoprecipitation assays were performed using RNA-Binding Protein Immunoprecipitation kit (Millipore, Burlington, MA) according to the manufacturer\'s instructions. 5 μg Rabbit anti-PKM2 (Cell Signaling Technology, Danvers, MA) and ATP5A1 (Sigma, St. Louis, MO) antibodies were used to perform RNA immunoprecipitation, respectively. The enrichment of *LINC01554* was determined by RT-PCR.

Dual luciferase reporter assay
------------------------------

3^\'^-UTR of *LINC01554* (GGGGCATT) and mutant form (CCCCGTAA) were separately subcloned into a pEZX-MT06 vector which contains the firefly luciferase gene (Genecopoeia, China) to establish two constructs, wt-*LINC01554*-luc and mutant-*LINC01554*-luc, respectively. The pRL-TK vector containing the Renilla luciferase gene acted as an internal control. Overexpression constructs, including miR-365a-3p mimics and control, were co-transfected with wt-*LINC01554*-luc and mutant- *LINC01554*-luc into BEL7402, respectively. Luciferase activities were detected 24 h after transfection by the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) according to the manufacturer\'s instructions.

Cycloheximide (CHX) chase assay
-------------------------------

To observe the degradation process of protein, CHX (MP biomedicals, Santa Ana, CA) was introduced to the cell culture medium at a final concentration of 100 ng/mL. Total protein was extracted at indicated time points and analyzed by western blotting.

*In vitro* ubiquitination assay
-------------------------------

Cells were treated with MG132 (10 μM, Selleck Chemicals, Houston, TX) for 10 h. Cell lysates were then collected and subjected to immunoprecipitation with rabbit anti-PKM2 antibody (1:50 dilution, \#4053, Cell Signaling Technology, Danvers, MA), eluted by 20 μL lysis buffer and denatured by SDS sample buffer (Thermo scientific, Rockford, IL). The elution was assessed by western blotting with rabbit anti-ubiquitin antibody (Table [S2](#SM0){ref-type="supplementary-material"}).

*In vitro* and *in vivo* Akt inhibitor assay
--------------------------------------------

For*in vitro* assay, 1 × 10^3^ *LINC01554*-transfected cells (7402-*LINC01554*, 7701-*LINC01554*) and *LINC01554*-KO (7721-KO) were seeded in 6-well-plate and treated with MK2206 (Selleck Chemicals, Houston, TX) in different concentrations (0.0, 0.5, 1.0, 5.0 μM) to examine the foci formation ability. 3 × 10^3^ cells were seeded in 96-well-plate to evaluate the cells growth rate with MK2206. For *in vivo* assay, 4-week-old male BALB/C nude mice (Guangdong Animal Center) were implanted subcutaneously at the right flank with 5 × 10^6^ *LINC01554*-transfected cells (7402-*LINC01554*, 7701-*LINC01554*). Two weeks later, mice were executed and the subcutaneous xenografts were isolated and cut into small pieces to bear in mice separately. Once the tumor volume reached to the range from 80 - 100 mm^3^, mice were randomly divided into two groups. MK2206 was dissolved in 30% (w/v) Captisol (Selleck Chemicals, Houston, TX) solution to optimize the solubility and stability [@B22]. Mice were administered orally with MK2206 at the dose of 100 mg/kg body weight and 30% Captisol (served as control) every second day for 2 weeks, respectively [@B23]. After isolation of xenograft tumors, each tumor was immediately frozen in liquid nitrogen for Western blot analysis. All animal experiments were conducted in compliance with the policies and regulations of Institutional Animal Care and Use Committee at Sun Yat-sen University Cancer Center.

Immunohistochemistry staining
-----------------------------

IHC study was performed according to a standard streptavidin-biotin-peroxidase complex method. Paraffin-embedded, formalin fixed sections were dewaxed by xylene, rehydrated using graded ethanol, rinsed with deionized water, and then blocked with 3% hydrogen peroxide for 10 min at room temperature. Antigen retrieval was performed by high-pressure-cooking the samples in a 10 mM citrate buffer (pH 6.0) for 4 min. Slides were blocked with 5% normal goat serum for 30 min at room temperature and subsequently incubated with primary antibody at 4 °C overnight. The usage information of primary antibodies was listed in Table [S2](#SM0){ref-type="supplementary-material"}. Slides were then incubated with an Envision detection system (DAKO), and the nucleus was counterstained by Meyer\'s hematoxylin.

Statistics
----------

Statistical analysis was performed using SPSS version 22.0 (SPSS, Chicago, IL). Paired student *t* test was used for analysis of *LINC01554* and miR-365a mRNA level in HCC specimens. Kaplan-Meier plots and log-rank tests were used for overall survival analysis. Pearson chi-square test was applied to analyzing clinical correlations between *LINC01554* and clinicopathologic parameters as well as the correlations between *LINC01554* and miR-365a-3p in HCC tumor tissues. Univariable and multivariable Cox proportional hazards regression models were performed to analyze independent prognostic factors. The independent Student *t* test was used to compare the cell growth rate, non-adherent colony formation, foci formation, tumor growth rate, glucose consumption, lactate production, ATP production and pyruvate production, etc. Results with *P* \< 0.05 were considered statistically significant.

Results
=======

LINC01554 is frequently downregulated in HCC
--------------------------------------------

To test expression status of *LINC01554* in HCC, qRT-PCR was performed to compare *LINC01554* expression level between 167 HCC and corresponding non-tumor tissues. Result showed that *LINC01554* expression level was significantly lower in tumor tissues compared with their adjacent non-tumor tissues (*P* \< 0.001, Figure [1](#F1){ref-type="fig"}A). Downregulation of *LINC01554* was detected in 135/167 (80.8%) of HCC tissues (Figure [1](#F1){ref-type="fig"}B). RT-PCR was also performed in 7 HCC cases and absent expression of *LINC01554* was detected in all HCC tissues (Figure [S3](#SM0){ref-type="supplementary-material"}A). Additionally, *LINC01554* was downregulated in HCC cell lines compared with the immortalized liver cell line MIHA (Figure [1](#F1){ref-type="fig"}C). Northern blot analysis further validated the expression of *LINC01554* in cells, which was extremely low in HCC cell line QGY7701, but notably high in MIHA (Figure [S3](#SM0){ref-type="supplementary-material"}B). We also explored *LINC01554* level in Lee\'s Cohort [@B24], Llovet\'s Cohort [@B25], Wurmbach\'s Cohort in oncomine, and TCGA datasheet. And the results were consistent with our findings (Figure [1](#F1){ref-type="fig"}D). Furthermore, in addition to HCC, *LINC01554* is frequently downregulated in cholangiocarcinoma, testicular germ cell tumors, skin cutaneous melanoma and ovarian cancer (Figure [S3](#SM0){ref-type="supplementary-material"}C). Subcellular fractionation analysis and LncRNAs FISH assay unraveled that *LINC01554* was primarily located in the cytoplasm (Figure [1](#F1){ref-type="fig"}E-F).

Clinical significance of LINC01554 in HCC
-----------------------------------------

The correlation between *LINC01554* downregulation and clinicopathologic features in 167 HCC samples was then statistically analyzed. We found that downregulation of *LINC01554* was significantly associated with adjacent organs invasion (*P* = 0.005), tumor size (*P* = 0.041) and tumor staging (*P* = 0.023, Table [1](#T1){ref-type="table"}). Kaplan-Meier analysis demonstrated downregulation of *LINC01554* was significantly associated with poorer overall survival in our cohort (n = 167, *P* = 0.035) and TCGA datasheet (n = 364, *P* \< 0.001, Figure [1](#F1){ref-type="fig"}G). Univariate Cox regression analysis revealed that microsatellite formation (*P* = 0.002), cirrhosis (*P* = 0.007), adjacent organs invasion (*P* \< 0.001), tumor size (*P* \< 0.001) and *LINC01554* downregulation (*P* = 0.004) were significantly related to overall survival (Table [2](#T2){ref-type="table"}). Multivariate Cox regression analysis indicated that downregulation of *LINC01554* was an independent prognostic factor of HCC patients (*P* = 0.017, Table [2](#T2){ref-type="table"}).

LINC01554 is downregulated by miR-365a
--------------------------------------

Emerging studies have illustrated that interaction between miRNAs and long noncoding RNAs was critical for lncRNAs regulation [@B26], [@B27]. By exploring two bioinformatic databases, TargetScan (<http://www.targetscan.org>) and miRanda (<http://www.microrna.org>), we found miR-365a-3p was a putative miRNA targeting *LINC01554* (Figure [S3](#SM0){ref-type="supplementary-material"}D). Upregulation of miR-365a-3p was identified significantly higher in HCC tissues compared with their adjacent non-tumor tissues (*P* \< 0.05, Figure [S3](#SM0){ref-type="supplementary-material"}E). Further, linear regression analyses showed the expression of miR-365a-3p was negatively correlated with *LINC01554* expression in 62 HCC specimens using qRT-PCR (R = -0.487, *P* \< 0.001, Figure [S3](#SM0){ref-type="supplementary-material"}F). We also detected miR-365a-3p in two HCC cells (BEL7402 and QGY7701) and MIHA cells and the result showed that miR-365a-3p level was significantly higher in HCC cells than that in MIHA cells (Figure [1](#F1){ref-type="fig"}H). Next, we separately transfected miR-365a-3p mimics and miR-control to BEL7402 and QGY7701 to evaluate the influence of miR-365a-3p on *LINC01554* mRNA expression level. *LINC01554* mRNA level was notably decreased in comparison to the control groups (Figure [1](#F1){ref-type="fig"}I). To further verify whether *LINC01554* is a direct target of miR-365a-3p, we established two constructs, wt-*LINC01554* 3\'-UTR and mutant *LINC01554* 3\'-UTR. Empty luciferase reporter construct served as a control. The relative luciferase activity in BEL7402 cells appeared significant diminishment after co-transfection of miR-365a-3p mimics and wt-*LINC01554*-luc, while the luciferase activity was not affected in empty vector group or mutant-*LINC01554-luc* group (Figure [1](#F1){ref-type="fig"}J). Collectively, these findings supported that miR-365a could directly downregulate *LINC01554*.

LINC01554 accelerates PKM2 degradation
--------------------------------------

Accumulating evidence has revealed that the subcellular localization of lncRNAs was strongly associated with their functions and mechanisms. For instance, lncRNAs in the cytoplasm may affect protein translational modifications or gene regulation by behaving as decoys for miRNAs and proteins [@B28],[@B29]. Since *LINC01554* mainly accumulates to the cytoplasm, we asked whether *LINC01554* would play a role in regulating cytoplasmic proteins through direct interaction. RNA pull-down assay thereby was conducted followed by mass spectrometry analysis to verify our hypothesis. Intriguingly, the results showed that *LINC01554* could pull-down a series of aerobic glycolytic enzymes (Table [S3](#SM0){ref-type="supplementary-material"}), suggesting that *LINC01554* might involve in regulation of glucose metabolism in HCC, especially in aerobic glycolysis. List of *LINC01554-*interacting proteins identified by mass spectrometry was also presented in Table [S4](#SM0){ref-type="supplementary-material"}.

Increasing evidences have demonstrated that cancer cells prefer to aerobic glycolysis since this unique metabolic pattern can provide more precursors for biosynthesis of macromolecules, such as nucleic acids, amino acids and lipids, which are essential for sustaining rapid division of cancer cells [@B30], [@B31]. In the *LINC01554* pull-down proteins, pyruvate kinase M2 (PKM2) drew our attention because pyruvate kinase was speed-limited enzymes in aerobic glycolytic pathway. As one of the isoforms of pyruvate kinase, PKM2 has been reported to enrich in rapid proliferative cells, such as embryonic cells and cancer cells [@B32]. RNA immunoprecipitation with two primary antibodies, PKM2 (Figure [2](#F2){ref-type="fig"}A) and ATP5A1 (Figure [S4](#SM0){ref-type="supplementary-material"}A) were applied to validate the result of mass spectrometry. The interaction between PKM2 and *LINC01554* was further validated in QGY7701 cells and BEL7402 cells (Figure [2](#F2){ref-type="fig"}A). Furthermore, RNA FISH combined with Immunofluorescence (IF) presented the colocalization of PKM2 and *LINC01554* in the cytoplasm (Figure [2](#F2){ref-type="fig"}B). Besides, we found that PKM2 protein level decreased in *LINC01554*-transfected BEL7402 and QGY7701 cells (Figure [2](#F2){ref-type="fig"}C, upper). To further confirm the impact of *LINC01554* on PKM2, we generated *LINC01554*- knockout (KO) cells by CRISPR/Cas9 in SMMC7721 cells. A number of clones were successfully edited, and two clones were used in this study (Figure [S4](#SM0){ref-type="supplementary-material"}B-D). The protein level of PKM2 was successfully rescued in *LINC01554*-KO SMMC7721 cells (Figure [2](#F2){ref-type="fig"}C, lower). To further validate the negative regulation role of *LINC01554* on PKM2, *LINC01554* mRNA levels and PKM2 protein levels were measured in 11 pairs of HCC tissues and corresponding non-tumor tissues. Relative intensity of each band was scanned and quantified by Quantity One (Bio-rad, Hercules, CA). And a negative correlation was observed between *LINC01554* and PKM2 (Figure [2](#F2){ref-type="fig"}D and Figure [S4](#SM0){ref-type="supplementary-material"}E). In Addition, RNA FISH of *LINC01554* and IF of PKM2 performed separately in clinical specimens also presented the similar pattern (Figure [2](#F2){ref-type="fig"}E).

Next, we tried to explore the molecular mechanism of the interaction between *LINC01554* and PKM2. Results from qRT-PCR showed that there was no significantly difference of PKM2 mRNA levels between *LINC01554*-transfected cells or *LINC01554*- KO cells and their controls (Figure [S4](#SM0){ref-type="supplementary-material"}F). Thus, we speculated *LINC01554* might regulate the protein stability of PKM2. Result from cycloheximide chase assay demonstrated that PKM2 in *LINC01554-* transfected cells behaved shorter half-life than that in control group (Figure [2](#F2){ref-type="fig"}F). However, effect of *LINC01554* on PKM2 was abolished in *LINC01554*-KO cells (Figure [2](#F2){ref-type="fig"}G). As more than 80% of protein degradation is related to the ubiquitin-proteasome pathway [@B33], we tested whether *LINC01554* was involved in the ubiquitin-mediated PKM2 degradation by *in vitro* ubiquitination assay. The result illustrated that the ubiquitin-mediated PKM2 degradation was enhanced in *LINC01554*-transfected cells compared with their controls (Figure [2](#F2){ref-type="fig"}H, left). The ubiquitin-mediated degradation effect of *LINC01554* on PKM2 was significantly abrogated in *LINC01554*-KO cells (Figure [2](#F2){ref-type="fig"}H, right). These results demonstrated that *LINC01554* downregulated PKM2 by ubiquitin-mediated degradation.

LINC01554 impairs aerobic glycolysis in HCC cells
-------------------------------------------------

Since *LINC01554* promotes degradation of PKM2, which is one of the isoform of pyruvate kinase, the speed-limited enzyme in the last step of glycolysis pathway, we raised a question about whether *LINC01554* could subsequently affect the metabolic phenotype in HCC cells. *LINC01554* was stably transfected into HCC cell lines BEL7402 and QGY7701 (Figure [S5](#SM0){ref-type="supplementary-material"}A). Glucose consumption, lactate production, pyruvate production and ATP level were then detected in *LINC01554*-transfected cells and their vectors respectively. Results showed that *LINC01554* could decrease glucose consumption (Figure [3](#F3){ref-type="fig"}A), lactate production (Figure [3](#F3){ref-type="fig"}B), pyruvate production (Figure [3](#F3){ref-type="fig"}C), and increase ATP level (Figure [3](#F3){ref-type="fig"}D). The inhibitory effect of *LINC01554* on aerobic glycolysis could be reversed when *LINC01554* was knocked out (Figure [3](#F3){ref-type="fig"}A-D). These results implied that *LINC01554* could inhibit aerobic glycolysis in HCC cells.

LINC01554 exerts strong tumor-suppressive function
--------------------------------------------------

Enhanced aerobic glycolytic effect has been recognized as the hallmark of cancer cells. More energetic requirements, which supplied by the intermediates generated from aerobic glycolysis, are needed for cancer cell division. Therefore, based on the observation that *LINC01554* inhibited the aerobic glycolysis in HCC cells, the suppressive impact of *LINC01554* on HCC tumorigenesis was then characterized by both *in vitro* and *in vivo* functional assays. Cell growth, non-adherent colony formation and foci formation assays were performed to assess the *in vitro* function of *LINC01554*. Compared with empty vector-transfected cells, *LINC01554*-transfected cells showed slower cell growth rate (Figure [3](#F3){ref-type="fig"}E), poorer colony formation ability in soft agar (Figure [3](#F3){ref-type="fig"}F) and lower foci formation frequency (Figure [3](#F3){ref-type="fig"}G). However, after introducing miR-365a-3p mimics, the inhibitory effect of *LINC01554* on cell growth was dramatically impaired (Figure [S5](#SM0){ref-type="supplementary-material"}B). To further study the tumor-suppressive role of *LINC01554 in vivo*, empty vector and *LINC01554*-transfected cells were injected subcutaneously to the left and right dorsal flanks of nude mice (n = 6), respectively. The result showed that tumors derived from *LINC01554*-transfected cells grew much slowly with smaller size and lighter weight, compared with tumors developed from empty vector-transfected cells (Figure [3](#F3){ref-type="fig"}H and Figure [S5](#SM0){ref-type="supplementary-material"}C). Both *in vitro* and *in vivo* tumor suppressive effects of *LINC01554* could be reversed in *LINC01554*-KO cells (Fig. [3](#F3){ref-type="fig"}E, G-H and Figure [S5](#SM0){ref-type="supplementary-material"}C). Moreover, proliferation marker Ki67 and expression of PKM2 by IHC staining was much lower in xenograft with *LINC01554*-transfected cells than that with empty-vector transfected cells, but higher in xenograft tumors developed from *LIN01554*-KO cells compared with xenograft tumors derived from *LINC01554*-WT cells (Figure [3](#F3){ref-type="fig"}I, Figure [S5](#SM0){ref-type="supplementary-material"}E). Thus, these findings strongly recommended that *LINC01554* exerted tumor-suppressive function.

LINC01554 inhibits Akt/mTOR signaling pathway
---------------------------------------------

To determine signaling pathway affected by *LINC01554* in inhibiting tumor growth, KEGG pathway analysis was performed using COEXPREdb [@B34], which was based on microarray and RNA-Seq data. The result showed that *LINC01554* was related to PI3K/Akt signaling pathway (Figure [S5](#SM0){ref-type="supplementary-material"}D), which plays pivotal role in cell proliferation. Also, combined with mTOR, PI3K/Akt/mTOR signaling pathway has been recognized as a central signaling pathway coordinating nutrient availability, including aerobic glycolysis [@B35]. Our result revealed that phosphorylated Akt (p-Akt) decreased in *LINC01554*-transfected cells compared with control cells (Figure [4](#F4){ref-type="fig"}A). mTOR is the downstream of Akt pathway and upstream of p70 S6 kinase. To examine the effect of *LINC01554* on mTOR pathway, phosphorylated mTOR (p-mTOR) and phosphorylated p70 S6 kinase (p-p70 S6K) were detected. In line with our hypothesis, p-mTOR and p-p70 S6K were all reduced in *LINC01554*-tranfected cells compared with vectors (Figure [4](#F4){ref-type="fig"}A, left). The inhibitory effect of *LINC01554* on Akt/mTOR pathway was abolished in *LINC01554*-KO cells (Figure [4](#F4){ref-type="fig"}A, right). Result from IHC staining also presented that p-Akt and p-mTOR expression level were lower in the xenograft tumors originated from *LINC01554*-transfected cells, but higher in xenograft tumors derived from *LINC01554*-KO cells compared to their vectors, respectively (Figure [S5](#SM0){ref-type="supplementary-material"}E). These findings strongly suggested that *LINC01554* could restrain Akt/mTOR pathway.

To further confirm the inhibitory role of *LINC01554* on Akt/mTOR signaling pathway and explore the clinical translation prospects of *LINC01554*, an Akt inhibitor, MK2206, was introduced to *in vitro* functional assays in both *LINC01554*- transfected cells and *LINC01554*-KO cells. MK2206 is a small molecular inhibitor of Akt and has been currently tested in the clinical trials of cancers treatment. In our study, both cell growth assay and foci formation assay were dramatically inhibited by MK2206 with the increasing concentrations in *LINC01554*-transfected cells compared to *LINC01554*- KO cells (Figure [4](#F4){ref-type="fig"}B-C). In addition, the phosphorylation of Akt and mTOR was markedly inhibited in a dose-dependent manner in *LINC01554*-transfected cells (Figure [4](#F4){ref-type="fig"}D). However, in *LINC01554*-KO cells, the suppressive impact of MK2206 on Akt and mTOR phosphorylation was attenuated (Figure [4](#F4){ref-type="fig"}D, the most right). Moreover, to determine whether *LINC01554* impaired aerobic glycolysis in HCC cells via Akt/mTOR signaling pathway, glucose metabolism was measured in *LINC01554*-KO cells after treatment with Akt inhibitor MK2206. Both glucose consumption and lactate production were decreased after introduction of MK2206 (Figure [S6](#SM0){ref-type="supplementary-material"}A-B).

To explore whether HCC patients with high expression of *LINC01554* would benefit from MK2206 as potential therapeutic strategy, HCC mice xenograft model derived from *LINC01554*-transfected cells was constructed. When subcutaneous tumors grew to the range from 80 - 100 mm^3^ in volume, MK2206 (100 mg/kg) in 30% captisol was administrated orally every second day for two weeks. Control groups were given 30% captisol. Notably, 2 weeks later, the MK2206 groups presented slower growth rate compared to vehicle groups in both BEL7402 and QGY7701 cells (Figure [4](#F4){ref-type="fig"}E). Proteins of xenograft tumors in different groups were extracted to validate the effect of MK2206 on AKT/mTOR pathway. As Figure [4](#F4){ref-type="fig"}F showed, phosphorylated mTOR was significantly decreased, indicating that Akt/mTOR pathway was effectively inhibited. These results further supported that *LINC01554* inhibited Akt/mTOR signaling pathway and more importantly, it might serve as an indicator for introducing MK2206 to HCC therapy.

Discussion
==========

Despite the pathogenesis of HCC has been widely investigated, the pivotal molecular mechanism for its initiation and progression still remains unclear, thereby restricting the development of effective therapeutic strategies. Recently, extensive studies have revealed that molecular aberration in metabolic events is strongly relevant to initiation and progression of cancers. It is well-known that increased aerobic glycolysis is one of the features of cancer cells, which has been exploited to detect and image tumors through positron emission tomography-computed tomography (PET/CT). As liver is an organ with high glucose metabolic activity, the dysfunction of sustaining glucose metabolism homeostasis may contribute to the pathogenesis of HCC. In the recent two decades, long noncoding RNAs has been proved to act crucial biological functions in embryonic development and diseases, including cancers. *LINC01554* has been reported to be associated with advancing fibrosis of non-alcoholic fatty liver disease (NAFLD) patients and survival of esophageal carcinoma patients in previous study [@B36], [@B37]. However, whether *LINC01554* contributes to HCC development is still unidentified. In this study, we found that *LINC01554* was frequently downregulated in HCCs. Clinical analysis reveals that downregulation of *LINC01554* is associated with adjacent organ invasion, tumor size, advanced tumor stage and poor prognosis of HCC patients. Besides HCC, Database exploring results also unraveled that *LINC01554* was downregulated in some cancers, including cholangiocarcinoma, testicular germ cell tumors, skin cutaneous melanoma and ovarian serous cystadenocarcinoma.

Extensive evidence in previous studies has illustrated the interaction between lncRNA and miRNA could act in the noncanonical function model [@B26], [@B38]-[@B39]. In the present study, we found miR-365a-3p could directly bind to *LINC01554* and subsequently downregulate its expression level. miR-365a has been reported to serve as an oncogene that promoting tumor growth and metastasis in laryngeal squamous cell carcinoma [@B40]. Here, we also found miR-365a-3p was upregulated in HCC cell lines and clinical samples, which was significantly associated with decreased *LINC01554* expression. Furthermore, our results prove that miR-365a-3p directly targeted 3\'-UTR of *LINC01554* to inhibit *LINC01554* expression at transcriptional level. These findings suggest that the high expression of miR-365a accounts for downregulation of *LINC01554* in HCC.

Functions of long noncoding RNAs are closely related to their subcellular localization [@B29]. Subcellular fractionation assay and RNA FISH showed that *LINC01554* mainly accumulated in the cytoplasm, suggesting that *LINC01554* might interact with cytoplasmic proteins. RNA immunoprecipitation was conducted and a series of glycolytic enzymes were validated. PKM2, one protein pulled down by *LINC01554*, drew our interest. PKM2 is a speed-limited enzyme at the late stage of glycolysis. It has been widely related to many human cancers [@B41]-[@B42]. Our further study found that *LINC01554* negatively regulated PKM2 through ubiquitin-mediated degradation. However, whether *LINC01554* promotes ubiquitination of PKM2 directly by shifting its conformational structure resulting in exposure of recognition domain to ubiquitin-proteins, or just serves as the scaffold to provide a platform for interaction between PKM2 and certain proteins remains to be further investigated.

Functional assays*in vitro* and *in vivo* revealed that *LINC01554* exerted tumor-suppressive function and impeded aerobic glycolysis. Enhanced aerobic glycolysis is a metabolic phenomenon of rapid proliferating cells, including cancer cells. PI3K/Akt/ mTOR pathway is one of the central signaling pathways to coordinate aerobic glycolytic and cellular biosynthesis in malignant cells [@B35]. Our finding unraveled that *LINC01554* could restrain Akt/mTOR signaling pathway to strengthen the inhibitory effect on aerobic glycolytic in HCC cells, ultimately abolishing the cell growth advantages. An Akt inhibitor, MK2206, was used to validate the inhibitory role of*LINC01554* on Akt/mTOR. MK2206 is an oral allosteric inhibitor of pan-Akt, which is able to block the autophosphorylation of threonine 308 and serine 473 domains of target proteins. Currently, it has been reported to be in the phase II clinical trials of many solid tumors, including non-small-cell and small cell lung carcinoma (NCT01306045), colon and rectal cancer (NCT01802320), breast carcinoma (NCT01776008) and hepatocellular carcinoma (NCT01239355). In line with our hypothesis, the inhibitory effect of MK2206 on cell growth, and phosphorylation of Akt and mTOR were attenuated in *LINC01554*-KO cells. Conversely, the cell proliferation, and phosphorylation of Akt and mTOR were significantly suppressed by MK2206 in *LINC01554*-transfected cells. Most importantly, *in vivo* functional assay suggests that patients with high expression of *LINC01554* might achieve better therapeutic effects from the Akt inhibitor MK2206.

In summary, our findings first define *LINC01554* as a tumor suppressor in hepatocellular carcinoma and it might serve as potential prognostic biomarker for HCC patients. *LINC01554* downregulation empowers cancer cells acquiring high aerobic glycolysis to sustain cells growth advantages, through regulating PKM2 and Akt/mTOR signaling pathway (Figure [4](#F4){ref-type="fig"}G). Last but not least, nude mice bearing tumors derived from *LINC01554-*transfected cells benefit more from oral administration of Akt inhibitor MK2206, which strongly recommends that *LINC01554* may provide rationale for precision therapy of MK2206 in HCC patients.
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![**LINC01554 is frequently downregulated in HCCs.** (A) Relative expression level of *LINC01554* detected by qRT-PCR in 167 HCC tissues and adjacent non-tumor tissues. Expression of β-actin was used as an internal control. (B) *LINC01554* expression fractions in 167 HCC tissues and adjacent non-tumor tissues. (C) Relative expression level of *LINC01554* detected by qRT-PCR in an immortalized liver cell line (MIHA) and HCC cell lines. Expression of β-actin was used as internal control. (D) RNA sequencing expression of *LINC01554* was analyzed in different cohorts, including Lee\'s cohort, Llovet\'s cohort, Wurmbach\'s cohort in oncomine (<https://www.oncomine.org>), and TCGA database. (E) Nuclear and cytoplasmic fractions of *LINC01554* in MIHA cells and SMMC7721 cells determined by qRT-PCR with U6 or β-actin as a nuclear or cytoplasmic internal control. (F) Representative images of subcellular localization of *LINC01554* (red) in MIHA cells, HCC tissues and adjacent non-tumor tissues detected by RNA FISH. Nuclei were stained with DAPI (blue). Scale bar, 20 μm in image of MIHA cells and 50 μm in images of adjacent non-tumor and HCC tissues. (G) Kaplan-Meier analysis revealed that low expression of *LINC01554* was related to poorer overall survival of HCC patients in both SYSUCC cohort (n = 167, *P* = 0.035) and TCGA database (n = 364, *P* \< 0.001). (H) The expression levels of miR-365a in MIHA, BEL7402 and QGY7701 cells determined by qRT-PCR with U6 as an internal control. (I) *LINC01554* expression levels were determined by qRT-PCR in BEL7402 cells and QGY7701 cells, after transient transfection of miR-365a-3p mimics and control. β-actin was served as an internal control (J) Relative luciferase activities were detected by Dual-Luciferase Reporter assays in BEL7402 cells after co-transfection of miR-365a-3p mimics or miR-control with wild-type-*LINC01554*-luc, mutant-*LINC01554*-luc or empty vector with pRL-TK. Error bars represent SD in triplicate experiments (\*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001 in independent Student\'s *t* test).](thnov09p0796g001){#F1}

![**LINC01554 accelerates PKM2 degradation by ubiquitin-mediated proteolysis.** (A) RIP assays of *LINC01554* in BEL7402 cells and QGY7701 cells using anti-PKM2 and IgG antibodies, respectively. The percentage of RIP-enriched RNA relative to input was determined by RT-PCR. Error bars represent SD in triplicate experiments (\*\*, *P* \< 0.01). (B) Representative images of co-staining *LINC01554* (red) and PKM2 (green) in BEL7402 cells and QGY7701 cells by combination of RNA FISH and immunofluorescence. Nuclei were stained with DAPI (blue). Scale bar = 20 μm. (C) PKM2 protein levels in *LINC01554*-transfected cells and knockout cells were analyzed by western blotting. (D) Representative images of *LINC01554* detected by RT-PCR and PKM2 by Western blotting (*left*). The line chart (*right*) revealed the negative correlation between *LINC01554* and PKM2 in 11 pairs of HCC tissues and adjacent non-tumor tissues. N, non-tumor tissue; T, tumor tissue. (E) Representative images of expression of *LINC01554* (red, detected by RNA FISH) and PKM2 (green, detected by immunofluorescence) in the same tumor tissue and adjacent non-tumor tissues. Scale bar = 50 μm. (F and G) CHX assays for observing PKM2 degradation rate in *LINC01554*-transfected cells, knockout cells and their vectors. Cells were treated with CHX (100 ng/mL) for the indicated time points. β-actin was used as a loading control. (H) *in vitro* ubiquitination assay in *LINC01554*-transfected cells, knockout cells and their vectors. All cells were incubated with MG132 (10 μM) for 10 h. Cell lysates were immunoprecipitated with anti-PKM2 antibody. The precipitates and input were analyzed by immunoblotting. Bottom panel, input of cell lysates. Vector, empty vector-transfected cells; *LINC01554*, *LINC01554*-transfected cells; WT, wild-type cells; KO, *LINC01554*-knockout cells.](thnov09p0796g002){#F2}

![**LINC01554 exerts tumor-suppressive function through inhibiting aerobic glycolysis in HCC cells.** Detection of glucose consumption (A), lactate production (B), pyruvate production (C), and intracellular ATP level (D) in *LINC01554*-transfected cells, knockout cells and their vectors. \*, *P* \< 0.05; \*\*, *P* \< 0.01 in independent Student\'s *t* test. (E) CCK8 proliferation assay was used to compare cell growth rates between *LINC01554*-transfected, *LINC01554*-knockout and their vectors. Non-adherent colony formation assays (F) and foci formation assays (G) and were used to compare colony formation abilities between *LINC01554*-transfected, *LINC01554*-knockout and their controls. Error bars represent SD in triplicate experiments (\*, *P* \< 0.05; \*\*, *P* \< 0.01 in independent Student\'s *t* test). (H) Images of xenograft tumors derived from *LINC01554*-transfected cells, knockout cells and their vectors in nude mice. Tumor growth curves were summarized in the line chart. The average tumor volume was expressed as the mean standard deviation of 6 mice (\*, *P* \< 0.05; \*\*, *P* \< 0.01 in independent Student\'s *t* test). (I) Representative IHC images of Ki67 expressions in xenograft tumors derived from *LINC01554-*transfected cells, *LINC01554*-knockout cells and their vectors. Scale bar = 50 μm. Vector, empty vector-transfected cells; *LINC01554*, *LINC01554*-transfected cells; WT, wild-type cells; KO, *LINC01554*-knockout cells.](thnov09p0796g003){#F3}

![**LINC01554 inhibits Akt/mTOR signaling pathway.** (A) Western blots analysis of Akt/mTOR signaling in *LINC01554*-transfected cells, knockout cells and their controls, including Akt, phospho-Akt (Ser473), mTOR, phospho-mTOR (Ser2448) and phospho-p70 S6 kinase (Ser371). Vector, empty vector-transfected cells; *LINC01554*, *LINC01554*-transfected cells; WT, wild-type cells; KO, *LINC01554*-knockout cells. Cell growth assay (B) and foci formation assay (C) of *LINC01554*-transfected and -knockout cells after treatment with varying concentrations of MK2206. Error bars represent SD in triplicate experiments (\*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001 in independent Student\'s *t* test). (D) Representative western blot analysis of Akt/mTOR signaling pathway, including Akt, phospho-Akt (Ser473), mTOR, phospho-mTOR (Ser2448) in *LINC01554*-transfected and -knockout cells that were treated with increasing concentrations of MK2206 for 24 h. β-actin served as loading control. (E) Representative images of nude mice bearing tumors derived from *LINC01554-*transfected cells after treatment with 100 mg/kg MK2206 and 30% captisol in saline (control) by gavage for 2 weeks. Tumor sizes in nude mice separately bearing xenograft tumors of BEL7402 and QGY7701 *LINC01554*-transfected cells were quantified. The average tumor size was expressed as the mean standard deviation of 6 mice (\*, *P* \< 0.05 in independent Student\'s *t* test). (F) Akt and mTOR signaling in indicated xenograft tumors were analyzed by western blotting. (G) A graphic illustration of the tumor-suppressive role of *LINC01554* in HCC. In HCC cells, *LINC01554* is downregulated by high expression of miR-365a, resulting in attenuating the ubiquitin-mediated degradation of PKM2 and inhibitory effect on Akt/mTOR signaling pathway, subsequently enhancing aerobic glycolytic level and eventually promoting proliferation of HCC cells.](thnov09p0796g004){#F4}

###### 

Clinicophathologic Correlation of LINC01554 Expression in HCC

  Features                       Total   *LINC01554* expression   *P*   
  ------------------------------ ------- ------------------------ ----- -------------
  Gender                                                                
  Male                           148     126                      22    0.477
  Female                         19      18                       1     
  Age (years)                                                           
  ≤60                            130     113                      17    
  \>60                           37      31                       6     
  Hepatitis B virus surface Ag                                          
  Negative                       24      22                       2     0.535
  Positive                       144     122                      21    
  Microsatellite formation                                              
  No                             121     103                      18    0.620
  Yes                            46      41                       5     
  Cirrhosis                                                             
  No                             33      29                       4     0.507
  Yes                            134     115                      19    
  Adjacent organs invasion                                              
  No                             131     108                      23    **0.005\***
  Yes                            36      36                       0     
  Tumor size (cm)                                                       
  ≤7                             97      79                       18    **0.041\***
  \>7                            70      65                       5     
  Tumor staging (AJCC)                                                  
  I-II                           102     83                       19    **0.023\***
  III-IV                         65      61                       4     

\**P* \< 0.05 represents statistically significant and is shown in bold.

###### 

Cox Proportional Hazards Model to analyze OS in 167 HCC patients.

  ------------------------------------------------------------------------------------------------------------------------------
  Clinicopathologic features   Univariate analysis   Multivariate analysis                                         
  ---------------------------- --------------------- ----------------------- --------------- ------- ------------- -------------
  Gender                       1.639                 0.706-3.803             0.250                                 

  Age (years)                  1.278                 0.757-2.158             0.358                                 

  HBV surface Ag               0.900                 0.461-1.757             0.758                                 

  Tumor staging (AJCC)         1.731                 0.753-3.814             0.153                                 

  Microsatellite formation     2.131                 1.325-3.427             **0.002\***     1.608   0.994-2.603   0.053

  Cirrhosis                    1.939                 1.195-3.147             **0.007\***     1.315   0.797-2.169   0.284

  Adjacent organs invasion     4.199                 2.418-7.293             **\<0.001\***   2.430   1.275-4.632   **0.007\***

  Tumor size (cm)              2.532                 1.598-4.012             **\<0.001\***   1.708   1.096-2.660   **0.018\***

  Downregulation of\           2.041                 1.248-3.081             **0.004\***     2.507   1.153-2.832   **0.017\***
  *LINC01554* in tumor                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------

*CI,* confidence interval. \**P* \< 0.05 represents statistically significant.
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